Clinical Trial Update: A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia [Phase 1]

View source ↗

Summary

This Phase 1 study compares tolerability of extended-release paliperidone (ER OROS) with immediate-release risperidone in adults with schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INVEGA (PALIPERIDONE)
• Risperdal (risperidone)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED